222 related articles for article (PubMed ID: 18446522)
1. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.
Tubic-Grozdanis M; Bolger MB; Langguth P
AAPS J; 2008; 10(1):213-26. PubMed ID: 18446522
[TBL] [Abstract][Full Text] [Related]
2. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
3. Biopharmaceutic classification of drugs revisited.
Daousani C; Macheras P
Eur J Pharm Sci; 2016 Dec; 95():82-87. PubMed ID: 27496048
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
5. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
7. Drug dissolution: significance of physicochemical properties and physiological conditions.
Jambhekar SS; Breen PJ
Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
[TBL] [Abstract][Full Text] [Related]
8. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
Melillo N; Aarons L; Magni P; Darwich AS
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
[TBL] [Abstract][Full Text] [Related]
9. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.
Sun L; Sun J; He Z
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):471-487. PubMed ID: 27447171
[TBL] [Abstract][Full Text] [Related]
11. Estimating drug solubility in the gastrointestinal tract.
Dressman JB; Vertzoni M; Goumas K; Reppas C
Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
[TBL] [Abstract][Full Text] [Related]
12. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
[TBL] [Abstract][Full Text] [Related]
13. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
14. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.
Gobeau N; Stringer R; De Buck S; Tuntland T; Faller B
Pharm Res; 2016 Sep; 33(9):2126-39. PubMed ID: 27278908
[TBL] [Abstract][Full Text] [Related]
16. In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models.
Sjögren E; Thörn H; Tannergren C
Mol Pharm; 2016 Jun; 13(6):1763-78. PubMed ID: 26926043
[TBL] [Abstract][Full Text] [Related]
17. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
18. Identification of biowaivers among Class II drugs: theoretical justification and practical examples.
Rinaki E; Dokoumetzidis A; Valsami G; Macheras P
Pharm Res; 2004 Sep; 21(9):1567-72. PubMed ID: 15497681
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
[TBL] [Abstract][Full Text] [Related]
20. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.
Hurst S; Loi CM; Brodfuehrer J; El-Kattan A
Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):469-89. PubMed ID: 17696800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
